UPDATE: Immunomedics Reports Plan To Initiate Phase 2 Pivotal TROPHY U-01 Study Of Sacituzumab Govitecan As Single Agent In Patients With Locally-Advanced Or Metastatic Urothelial Cancer Who Have Relapsed After Platinum-Based Regimen